Caribou Biosciences (CRBU) EBITDA (2020 - 2026)
Caribou Biosciences (CRBU) reported EBITDA of -$25.2 million for Q1 2026, up 37.1% year-over-year from -$18.4 million in Q1 2025, and up 4.79% on a QoQ basis from -$26.5 million in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of EBITDA data on file, last reported at -$25.2 million in Q1 2026.
- Quarterly EBITDA rose 37.1% year-over-year to -$25.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.4 million (up 9.48% YoY) and the FY2025 annual result came in at -$148.3 million, changed 0.41% from the prior year.
- EBITDA advanced to -$25.2 million in Q1 2026 per CRBU's latest filing, from -$26.5 million in the prior quarter.
- Across five years, EBITDA topped out at -$9.8 million in Q3 2023 and bottomed at -$54.2 million in Q2 2025.
- The 5-year median for EBITDA is -$27.5 million (2025), against an average of -$30.8 million.
- The widest annual swing landed in 2023, when EBITDA soared 63.67%; it then slumped 240.98% in 2024.
- Tracing CRBU's EBITDA over 5 years: stood at -$26.5 million in 2022, then decreased by 26.53% to -$33.5 million in 2023, then dropped by 7.55% to -$36.0 million in 2024, then rose by 26.5% to -$26.5 million in 2025, then gained by 4.79% to -$25.2 million in 2026.
- Per Business Quant, the three latest CRBU EBITDA figures stand at -$25.2 million (Q1 2026), -$26.5 million (Q4 2025), and -$27.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -25.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.21 Mn |
| Dec 31, 2025 | -26.48 Mn |
| Sep 30, 2025 | -27.50 Mn |
| Jun 30, 2025 | -54.23 Mn |
| Mar 31, 2025 | -40.08 Mn |
| Dec 31, 2024 | -36.02 Mn |
| Sep 30, 2024 | -33.58 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -41.59 Mn |
| Dec 31, 2023 | -33.49 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -29.93 Mn |
| Mar 31, 2023 | -27.26 Mn |
| Dec 31, 2022 | -26.47 Mn |
| Sep 30, 2022 | -27.10 Mn |
| Jun 30, 2022 | -27.19 Mn |
| Mar 31, 2022 | -20.04 Mn |
| Dec 31, 2021 | -18.61 Mn |
| Sep 30, 2021 | -20.97 Mn |
| Jun 30, 2021 | -14.31 Mn |
| Mar 31, 2021 | -13.16 Mn |
| Dec 31, 2020 | -15.21 Mn |
| Sep 30, 2020 | -8.23 Mn |
| Jun 30, 2020 | -2.26 Mn |
| Mar 31, 2020 | -10.43 Mn |